关注
Dr. Stanley Zhou, PhD
Dr. Stanley Zhou, PhD
Arsenal Biosciences Inc. (Previously: Princess Margaret Cancer Centre)
在 mail.utoronto.ca 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19
JT Hua, M Ahmed, H Guo, Y Zhang, S Chen, F Soares, J Lu, S Zhou, ...
Cell 174 (3), 564-575. e18, 2018
2922018
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Q Wu, W Ba-Alawi, G Deblois, J Cruickshank, S Duan, E Lima-Fernandes, ...
Nature communications 11 (1), 4205, 2020
1802020
TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer
KJ Kron*, A Murison*, S Zhou, V Huang, TN Yamaguchi, YJ Shiah, ...
Nature genetics 49 (9), 1336, 2017
1802017
A chemical toolbox for the study of bromodomains and epigenetic signaling
Q Wu, D Heidenreich, S Zhou, S Ackloo, A Krämer, K Nakka, ...
Nature communications 10 (1), 1915, 2019
1172019
Emergence of the noncoding cancer genome: a target of genetic and epigenetic alterations
S Zhou, AE Treloar, M Lupien
Cancer discovery 6 (11), 1215-1229, 2016
932016
Pioneer of prostate cancer: past, present and the future of FOXA1
M Teng*, S Zhou*, C Cai, M Lupien, HH He
Protein & Cell, 1-10, 2020
912020
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
S Zhou, JR Hawley, F Soares, G Grillo, M Teng, SA Madani Tonekaboni, ...
Nature communications 11 (1), 441, 2020
672020
The transition from quiescent to activated states in human hematopoietic stem cells is governed by dynamic 3D genome reorganization
N Takayama, A Murison, S Takayanagi, C Arlidge, S Zhou, L Garcia-Prat, ...
Cell stem cell 28 (3), 488-501. e10, 2021
582021
Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors
P Mazrooei*, KJ Kron*, Y Zhu‡, S Zhou‡, G Grillo, T Mehdi, M Ahmed, ...
Cancer cell 36 (6), 674-689. e6, 2019
552019
CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer
M Ahmed, F Soares, JH Xia, Y Yang, J Li, H Guo, P Su, Y Tian, HJ Lee, ...
Nature communications 12 (1), 1781, 2021
382021
Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
JR Hawley*, S Zhou*, C Arlidge, G Grillo, KJ Kron, R Hugh-White, ...
Cancer Research 81 (23), 5833-5848, 2021
11*2021
Transposable elements are co-opted as oncogenic regulatory elements by lineage-specific transcription factors in prostate cancer
G Grillo, T Keshavarzian, S Linder, C Arlidge, L Mout, A Nand, M Teng, ...
Cancer discovery 13 (11), 2470-2487, 2023
52023
Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer
S Cameron, G Deblois, JR Hawley, A Qamra, S Zhou, SAM Tonekaboni, ...
Oncogene 42 (21), 1693-1703, 2023
52023
Abstract LB196: An atlas of accessible chromatin in advanced prostate cancer
R Shrestha, LN Chesner, M Zhang, S Zhou, A Foye, A Lundberg, ...
Cancer Research 84 (7_Supplement), LB196-LB196, 2024
2024
AB-2100, a PSMA-inducible CA9-specific CAR T cell product for the treatment of ccRCC provides long-term tumor responses in preclinical mouse model
S Mohanty, J Chen, A Gomez, A Boroughs, I Scarfo, L Lim, K Dang, ...
Cancer Research 84 (6_Supplement), 38-38, 2024
2024
Development of AB-2100, an autologous integrated circuit T (ICT) cell therapy targeting CA9 intended for the treatment of ccRCC.
M Landon, I Scarfo, M Chew, R Sudhakah, M Nguyen, S Mohanty, J Chen, ...
Journal of Clinical Oncology 42 (4_suppl), 472-472, 2024
2024
301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC
I Scarfo, L Lim, K Dang, M Chew, R Sudhakah, M Nguyen, S Mohanty, ...
Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023
2023
Abstract LB092: Identification of target antigens for logic-gated CAR-T therapeutics for the treatment of clear cell renal cell carcinoma: conditional targeting of CA9 with a …
N Attanasio, L Gray-Rupp, S Zhou, SA Williams
Cancer Research 83 (8_Supplement), LB092-LB092, 2023
2023
Multiplexed shRNA cassettes targeting orthogonal pathways (FAS/PTPN2/TGFBR) enhance the potency of integrated circuit T cells (ICTs) in multiple solid tumor models
TJ Gardner, A Litterman, BK Singh, L Silva, M Hari, S Zhou, C Tang, ...
Cancer Research 83 (7_Supplement), 1768-1768, 2023
2023
Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer
M Lupien, S Cameron, G Deblois, J Hawley, A Qamra, S Zhou, ...
2022
系统目前无法执行此操作,请稍后再试。
文章 1–20